带状疱疹与带状疱疹后神经痛:预防和管理
带状疱疹由水痘-带状疱疹病毒再激活引起,美国每年约100万例,个体终生风险30%。免疫功能下降者风险高20至100倍。皮疹前可有2至3天前驱症状,皮疹通常单侧、局限单一皮节,7至10天结痂。抗病毒治疗最好在皮疹出现72小时内开始。带状疱疹后神经痛是最常见并发症,约五分之一患者发生。疫苗可降低发病率,CDC建议60岁及以上成人接种。
要点
- 皮疹出现72小时内启动阿昔洛韦、伐昔洛韦或泛昔洛韦抗病毒治疗。
- 带状疱疹后神经痛定义为急性带状疱疹后皮节分布区疼痛持续至少90天。
- 治疗以控制症状为主,可用利多卡因或辣椒素外用及加巴喷丁等口服药。
核心结论
- 带状疱疹由水痘-带状疱疹病毒再激活引起,美国每年约100万例,个体终生风险30%。
- 免疫功能下降者发生带状疱疹的风险高20至100倍。
- 带状疱疹后神经痛是最常见并发症,约五分之一患者发生。
- 水痘-带状疱疹病毒疫苗可降低带状疱疹发病率。
研究设计与样本
- 本文为综述,汇总带状疱疹与带状疱疹后神经痛的预防和管理证据。
主要发现
- 皮疹前可有2至3天乏力、头痛、低热和异常皮肤感觉。
- 皮疹通常单侧、局限单一皮节,7至10天内进展为清亮水疱、浑浊并结痂。
- 带状疱疹后神经痛定义为急性带状疱疹后皮节分布区疼痛持续至少90天。
- 带状疱疹后神经痛治疗以控制症状为主,包括利多卡因或辣椒素外用及加巴喷丁、普瑞巴林或三环类抗抑郁药口服。
关键数值与推荐
- 抗病毒治疗可选阿昔洛韦、伐昔洛韦或泛昔洛韦,最好在皮疹出现72小时内开始。
- 水痘-带状疱疹病毒疫苗获批用于50岁及以上成人。
- CDC免疫实践咨询委员会推荐该疫苗用于60岁及以上成人,某些免疫抑制患者除外。
临床怎么用
- 对疑似带状疱疹患者,应尽早(最好皮疹出现72小时内)启动抗病毒治疗。
- 对带状疱疹后神经痛患者,采用外用利多卡因或辣椒素及口服加巴喷丁、普瑞巴林或三环类抗抑郁药控制症状。
- 对60岁及以上成人(某些免疫抑制患者除外),按CDC建议评估并推荐水痘-带状疱疹病毒疫苗接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Herpes zoster, or shingles, is caused by reactivation of varicella zoster virus, which causes chickenpox. There are an estimated 1 million cases in the Unites States annually, with an individual lifetime risk of 30%. Patients with conditions that decrease cell-mediated immunity are 20 to 100 times more likely to develop herpes zoster. Patients may present with malaise, headache, low-grade fever, and abnormal skin sensations for two to three days before the classic maculopapular rash appears. The rash is usually unilateral, confined to a single dermatome, and typically progresses to clear vesicles that become cloudy and crust over in seven to 10 days. Herpes zoster can be treated with acyclovir, valacyclovir, or famciclovir, ideally within 72 hours of the development of the rash. Postherpetic neuralgia is the most common complication, occurring in about one in five patients. It is defined as pain in a dermatomal distribution sustained for at least 90 days after acute herpes zoster. Treatment is focused on symptom control and includes topical lidocaine or capsaicin and oral gabapentin, pregabalin, or tricyclic antidepressants. The varicella zoster virus vaccine decreases the incidence of herpes zoster and is approved for adults 50 years and older. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends this vaccine for adults 60 years and older, except for certain immunosuppressed patients.
引用
- Saguil A, Kane S, Mercado M, et al. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. Am Fam Physician. 2017. PMID: 29431387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。